Volume 8 Supplement 1

14th Scientific Symposium of the Austrian Pharmacological Society (APHAR)

Open Access

Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias

  • Andrea Hölbl1,
  • Christian Schuster1,
  • Boris Kovacic2,
  • Maria Hölzl1,
  • Sabine Fajmann1,
  • Florian Grebien3,
  • Lothar Hennighausen4,
  • Yongzhi Cui4,
  • Richard Moriggl5,
  • Hartmut Beug2 and
  • Veronika Sexl1Email author
BMC Pharmacology20088(Suppl 1):A4


Published: 5 November 2008

The Stat5 transcription factors Stat5a and Stat5b have been implicated in lymphoid development and transformation. Using the complete Stat5 knockout mice, we have previously shown that Stat5a/bnull/nullcells were resistant to transformation and leukemia development induced by Abelson oncogenes, whereas Stat5a/bΔN/ΔNcells readily transformed. So far, these findings showed distinct susceptibility to Abelson-induced transformation of Stat5a/bΔN/ΔNand Stat5a/bnull/nullmice and defined Stat5 as key regulator of initial transformation. In this study, we tested whether Stat5a/b is also essential for the maintenance of a transformed state. Therefore we developed a system, where Stat5a/b could be deleted at will. Abelson-transformed B lymphoid cells were generated from Stat5a/bfl/flgene targeted mice that had been crossed with Mx-Cre transgenic animals. These leukemic Stat5a/bfl/flMxCre cells were then used to test effects of Stat5a/b ablation in vitro and in vivo. In vitro, Stat5a/b deletion resulted in a cell cycle arrest followed by apoptosis. Nine days after deletion, no viable cells could be detected. In line with that, a down-regulation of Stat5 target genes mediating G1/S transition within the cell cycle and viability, such as cyclin D2 and cyclin D3, c-myc and bcl-xL was found. When leukemic Stat5a/bfl/flMxCre cells were injected into wild type or immuno-compromised mice leukemia rapidly developed. Again, deletion of Stat5a/b in vivo within the leukemic cells significantly counteracted disease progression as indicated by an increase of leukemia latency from 16 to 49 days. Eventually, all animals succumbed to a Stat5a/b-positive leukemia indicating that a few residual cells escaped deletion. Moreover, p53 abruption or overexpression of the oncogene did not alter the susceptibility to Stat5 loss of established leukemic cell lines. Taken together our data define a key role for Stat5a/b not only for lymphoid development but also for lymphoid transformation. Stat5a/b is necessary for the initial transformation as well as for leukemia progression. This absolute necessity for the proliferation and viability of Abelson-transformed cells puts Stat5a/b into the spotlight of new therapeutic strategies for the treatment of bcr/abl-induced leukemias.

Authors’ Affiliations

Centre of Biomolecular Medicine and Pharmacology, Medical University of Vienna
Institute of Molecular Pathology (IMP)
Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
NIDDK, National Institute of Health
Ludwig-Boltzmann Institute for Cancer Research (LBI-CR)


© Hölbl et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.